200 related articles for article (PubMed ID: 27321171)
1. Clinical and economic consequences of treating patients with peripheral neuropathic pain with brand name or generic drugs in routine clinical practice: The effects of age and sex.
Navarro-Artieda R; Rejas-Gutiérrez J; Pérez-Paramo M; Sicras-Mainar A
Neurologia (Engl Ed); 2018 Apr; 33(3):141-153. PubMed ID: 27321171
[TBL] [Abstract][Full Text] [Related]
2. Cost of treatment of peripheral neuropathic pain with pregabalin or gabapentin in routine clinical practice: impact of their loss of exclusivity.
Sicras-Mainar A; Rejas-Gutiérrez J; Pérez-Páramo M; Navarro-Artieda R
J Eval Clin Pract; 2017 Apr; 23(2):402-412. PubMed ID: 27671223
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness and costs of generic and brand-name gabapentin and venlafaxine in patients with neuropathic pain or generalized anxiety disorder in Spain.
Sicras-Mainar A; Rejas-Gutiérrez J; Navarro-Artieda R
Clinicoecon Outcomes Res; 2015; 7():299-312. PubMed ID: 26082655
[TBL] [Abstract][Full Text] [Related]
4. Consequences on economic outcomes of generic versus brand-name drugs used in routine clinical practice: the case of treating peripheral neuropathic pain or generalized anxiety disorder with pregabalin.
Sicras-Mainar A; Rejas-Gutiérrez J; Pérez-Paramo M; Sánchez-Alvarez L; Navarro-Artieda R; Darbà J
Expert Rev Pharmacoecon Outcomes Res; 2019 Feb; 19(1):45-57. PubMed ID: 30182806
[TBL] [Abstract][Full Text] [Related]
5. Costs and health resources utilization following switching to pregabalin in individuals with gabapentin-refractory neuropathic pain: a post hoc analysis.
Navarro A; Saldaña MT; Pérez C; Masramón X; Rejas J
Pain Pract; 2012 Jun; 12(5):382-93. PubMed ID: 22004531
[TBL] [Abstract][Full Text] [Related]
6. Pregabalin and gabapentin in matched patients with peripheral neuropathic pain in routine medical practice in a primary care setting: Findings from a cost-consequences analysis in a nested case-control study.
Pérez C; Navarro A; Saldaña MT; Masramón X; Rejas J
Clin Ther; 2010 Jul; 32(7):1357-70. PubMed ID: 20678683
[TBL] [Abstract][Full Text] [Related]
7. Cost analysis of adding pregabalin or gabapentin to the management of community-treated patients with peripheral neuropathic pain.
Sicras-Mainar A; Rejas-Gutiérrez J; Navarro-Artieda R; Planas-Comes A
J Eval Clin Pract; 2012 Dec; 18(6):1170-9. PubMed ID: 21883712
[TBL] [Abstract][Full Text] [Related]
8. [Clinical and economic consequences in patients initiating therapy with clopidogrel brand-name vs. generic: A real-life retrospective study].
Sicras-Mainar A; Escobar-Cervantes C; Micó-Pérez RM; Llisterri-Caro JL
Semergen; 2020; 46(1):16-26. PubMed ID: 31345684
[TBL] [Abstract][Full Text] [Related]
9. Pain alleviation and patient-reported health outcomes following switching to pregabalin in individuals with gabapentin-refractory neuropathic pain in routine medical practice.
Saldaña MT; Pérez C; Navarro A; Masramón X; Rejas J
Clin Drug Investig; 2012 Jun; 32(6):401-12. PubMed ID: 22480279
[TBL] [Abstract][Full Text] [Related]
10. Treatment persistence and adherence and their consequences on patient outcomes of generic versus brand-name statins routinely used to treat high cholesterol levels in Spain: a retrospective cost-consequences analysis.
Sicras-Mainar A; Sánchez-Álvarez L; Navarro-Artieda R; Darbà J
Lipids Health Dis; 2018 Dec; 17(1):277. PubMed ID: 30522491
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of a lidocaine 5% medicated plaster compared with gabapentin and pregabalin for treating postherpetic neuralgia: a german perspective.
Liedgens H; Hertel N; Gabriel A; Nuijten M; Dakin H; Mitchell S; Nautrup BP
Clin Drug Investig; 2008; 28(9):583-601. PubMed ID: 18666805
[TBL] [Abstract][Full Text] [Related]
12. Pregabalin versus gabapentin in the management of peripheral neuropathic pain associated with post-herpetic neuralgia and diabetic neuropathy: a cost effectiveness analysis for the Greek healthcare setting.
Athanasakis K; Petrakis I; Karampli E; Vitsou E; Lyras L; Kyriopoulos J
BMC Neurol; 2013 Jun; 13():56. PubMed ID: 23731598
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: a Canadian perspective.
Tarride JE; Gordon A; Vera-Llonch M; Dukes E; Rousseau C
Clin Ther; 2006 Nov; 28(11):1922-34. PubMed ID: 17213013
[TBL] [Abstract][Full Text] [Related]
14. Costs of pregabalin or gabapentin for painful diabetic peripheral neuropathy.
Udall M; Harnett J; Mardekian J
J Med Econ; 2012; 15(2):361-70. PubMed ID: 22181052
[TBL] [Abstract][Full Text] [Related]
15. Cost comparison of adding pregabalin or gabapentin for the first time to the therapy of patients with painful axial radiculopathy treated in Spain.
Sicras-Mainar A; Rejas-Gutiérrez J; Navarro-Artieda R; Planas-Comes A
Clin Exp Rheumatol; 2013; 31(3):372-81. PubMed ID: 23432967
[TBL] [Abstract][Full Text] [Related]
16. A systematic review of pharmacoeconomic studies for pregabalin.
Parker L; Huelin R; Khankhel Z; Wasiak R; Mould J
Pain Pract; 2015 Jan; 15(1):82-94. PubMed ID: 24815038
[TBL] [Abstract][Full Text] [Related]
17. Adding pregabalin or gabapentin for the management of community-treated patients with painful diabetic peripheral neuropathy: a comparative cost analysis.
Sicras A; Rejas J; Navarro R; Planas A
Clin Drug Investig; 2013 Nov; 33(11):825-35. PubMed ID: 24085589
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of a lidocaine 5% medicated plaster relative to gabapentin for postherpetic neuralgia in the United Kingdom.
Dakin H; Nuijten M; Liedgens H; Nautrup BP
Clin Ther; 2007 Jul; 29(7):1491-507. PubMed ID: 17825701
[TBL] [Abstract][Full Text] [Related]
19. Switching from pathogenetic treatment with alpha-lipoic acid to gabapentin and other analgesics in painful diabetic neuropathy: a real-world study in outpatients.
Ruessmann HJ;
J Diabetes Complications; 2009; 23(3):174-7. PubMed ID: 18403218
[TBL] [Abstract][Full Text] [Related]
20. A randomized controlled trial of amitriptyline versus gabapentin for complex regional pain syndrome type I and neuropathic pain in children.
Brown S; Johnston B; Amaria K; Watkins J; Campbell F; Pehora C; McGrath P
Scand J Pain; 2016 Oct; 13():156-163. PubMed ID: 28850523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
